Rituximab represents the frontline approach in patients with symptomatic anemia or disabling cold-induced peripheral symptoms and is effective in 50-60% of cases. Refractory/relapsing patients are an unmet need and may now benefit from complement inhibitors, particularly the anti-C1s sutimlimab, effective in controlling hemolysis thus improving anemia in >80% of patients, but not active on cold-induced peripheral symptoms. Novel drugs include long-acting complement inhibitors, plasma cells, and B-cell targeting agents (proteasome inhibitors, anti-CD38, BTKi, PI3Ki, anti-BAFF). Combination therapy may be the future answer to CAD unmet needs.
Keyphrases
- newly diagnosed
- end stage renal disease
- chronic kidney disease
- combination therapy
- ejection fraction
- peritoneal dialysis
- coronary artery disease
- machine learning
- prognostic factors
- high glucose
- diabetic rats
- physical activity
- diffuse large b cell lymphoma
- induced apoptosis
- radiation therapy
- cancer therapy
- signaling pathway
- current status
- lymph node
- iron deficiency
- drug delivery
- neural network